Globus Medical Inc. (GMED)
Globus Medical Q1 Earnings Call Highlights
Globus Medical NYSE: GMED reported a strong start to 2026, with first-quarter revenue and earnings rising sharply as the company cited continued momentum in U.S. spine, margin expansion and contributions from its Nevro acquisition.
GMED Stock Rises on Q1 Earnings & Revenue Beat, '26 EPS View Raised
Globus Medical beats Q1 EPS estimates by 22% as revenues rise 27% to $759.9M; margins widen and 2026 EPS outlook up, lifting shares 5.8%.
Globus Medical (GMED) Tops Q1 Earnings and Revenue Estimates
Globus Medical (GMED) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.68 per share a year ago.
Globus Medical, Inc. (GMED) Q1 2026 Earnings Call Transcript
Globus Medical, Inc. (GMED) Q1 2026 Earnings Call Transcript
Compared to Estimates, Globus Medical (GMED) Q1 Earnings: A Look at Key Metrics
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Globus Medical (GMED) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
GMED vs. IDXX: Which Stock Should Value Investors Buy Now?
Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Idexx Laboratories (IDXX). But which of these two stocks is more attractive to value investors?
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is This the Right Time to Add Globus Medical Stock to Your Portfolio?
GMED rides on NuVasive synergies, strong cash flow and rapid innovation, but macro pressures and rising costs cloud its near-term outlook.
All You Need to Know About Globus Medical (GMED) Rating Upgrade to Strong Buy
Globus Medical (GMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Why Is Globus Medical (GMED) Down 9.2% Since Last Earnings Report?
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock?
